DPyPE
Based on 1 Customer Validation
DPyPE is a neutral phosphatidylethanolamine lipid composed of a polyisoprene alkyl chain with two pyridine-containing phosphine ligands. DPyPE is mainly used in liposome formulations and to enhance the efficiency of gene delivery in vitro and in vivo. For example, DPyPE can be mixed with cationic lipids such as VC1052 (HY-156616) (in a 1:1 ratio) to form the vaccine adjuvant Vaxfectin (HY-142998). DPyPE assists VC1052 in binding to negatively charged pDNA to form a uniform liposome complex by regulating the fluidity and stability of the liposome membrane.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 98.0%
- CAS No.: 201036-16-0
- Formule: C45H90NO8P
- Masse moléculaire:804.17
-
Stockage:
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Activité biologique
DPyPE, as a neutral auxiliary lipid, enhances the structural stability of liposomes, prevents excessive aggregation of cationic lipids, and may also assist the complex to enter antigen-presenting cells. DPyPE does not directly participate in transfection, but indirectly enhances the immune response by optimizing the properties of liposomes, making Vaxfectin an adjuvant focused on activating humoral immunity[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
The preparation and experimental operation steps of liposome complexes in the literature are as follows[2]:
1. Liposome preparation
Cationic lipid VC1052 and neutral lipid DPyPE were dissolved in chloroform at a molar ratio of 1:1, mixed, and the solvent was evaporated by nitrogen flow in a sterile glass vial to form a dry lipid film.
Vacuum drying overnight to remove residual solvent, each vial contains 1.5 μmol of VC1052 and DPyPE.
Add 1 mL of sterile water for injection (SWFI) to each bottle and vortex at maximum speed for 5 minutes on a vortex mixer to form a liposome solution (concentration of 1.5 mM).
2. Preparation of pDNA-liposome complexes
Prepare liposomes (in SWFI) and pDNA (dissolved in 2× carrier) at 2 times the final concentration.
Slowly inject an equal volume of liposomes into the pDNA solution using a syringe at a pDNA (phosphate): cationic lipid molar ratio of 8:1, 4:1, or 2:1, while pushing at a constant speed using a 26-28 gauge needle.
Gently vortex for a few seconds (vortex mixer 4) to form a uniform liposome-pDNA complex (stable for several hours at room temperature and needs to be injected within 20 minutes to 1.5 hours).
3. Animal injection
Mouse: In the awake state, 50 μL of the complex was injected into the quadriceps femoris with a 28-gauge needle, containing 1-25 μg pDNA on each side of the muscle, and single or multiple booster injections were used.
Rabbit: After anesthesia, 300 μl of the complex was injected into the quadriceps femoris with a 22-gauge needle (or a needle-free injection device was used), with a dose of 150 μg pDNA.
4. Detection indicators
The anti-NP antibody titer in the serum was detected by ELISA, the antigen-specific plasma cells in the bone marrow were counted by ELISPOT, and the muscle transfection efficiency was evaluated by β-galactosidase activity assay.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 201036-16-0
-
Appearance Oil
-
Masse moléculaire 804.17
-
Formule C45H90NO8P
-
Color Off-white to light yellow
-
SMILES
NCCOP(OC[C@H](OC(CC(C)CCCC(C)CCCC(C)CCCC(C)C)=O)COC(CC(C)CCCC(C)CCCC(C)CCCC(C)C)=O)(O)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
-20°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvant et solubilité
DMSO : 200 mg/mL (248.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (3.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (3.11 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (269 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Ferrari ME, et al. Synergy between cationic lipid and co-lipid determines the macroscopic structure and transfection activity of lipoplexes. Nucleic Acids Res. 2002 Apr 15;30(8):1808-16. [Content Brief]
[2]. Hartikka J, et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine. 2001 Feb 28;19(15-16):1911-23. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.2435 mL | 6.2176 mL | 12.4352 mL | 31.0880 mL |
| 5 mM | 0.2487 mL | 1.2435 mL | 2.4870 mL | 6.2176 mL | |
| 10 mM | 0.1244 mL | 0.6218 mL | 1.2435 mL | 3.1088 mL | |
| 15 mM | 0.0829 mL | 0.4145 mL | 0.8290 mL | 2.0725 mL | |
| 20 mM | 0.0622 mL | 0.3109 mL | 0.6218 mL | 1.5544 mL | |
| 25 mM | 0.0497 mL | 0.2487 mL | 0.4974 mL | 1.2435 mL | |
| 30 mM | 0.0415 mL | 0.2073 mL | 0.4145 mL | 1.0363 mL | |
| 40 mM | 0.0311 mL | 0.1554 mL | 0.3109 mL | 0.7772 mL | |
| 50 mM | 0.0249 mL | 0.1244 mL | 0.2487 mL | 0.6218 mL | |
| 60 mM | 0.0207 mL | 0.1036 mL | 0.2073 mL | 0.5181 mL | |
| 80 mM | 0.0155 mL | 0.0777 mL | 0.1554 mL | 0.3886 mL | |
| 100 mM | 0.0124 mL | 0.0622 mL | 0.1244 mL | 0.3109 mL |